Overall, these results indicate that hepatic activation of the NF-κB signaling pathway not only promotes the progression of liver steatosis, likely by increased cholesterol synthesis but also drives liver inflammation at a later stage of MAFLD. Here, NFKB1 is linked to fatty liver disease.